Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and
preventing hospitalization in patients with heart failure and reduced ejection fraction …

Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in
patients with New York Heart Association class IV heart failure with a reduced ejection …

Abstract Study Objective To assess the effectiveness of sacubitril/valsartan versus
angiotensin receptor antagonist therapy for prevention of heart failure (HF)‐related …

Background Compared to heart failure patients with higher systolic blood pressure (SBP),
those with lower SBP have a worse prognosis. To make matters worse, the latter patients …

Sacubitril/valsartan has become an important first-line drug for symptomatic heart failure
(HF) patients, especially with left ventricular (LV) ejection fraction (LVEF)< 50%. However …

Background Heart failure (HF) is a growing public health problem. Sacubitril/valsartan is
now recommended to be used in persistently symptomatic patients with left ventricular …

Objectives: The aim of this study was to assess the prevalence and variation in angiotensin
receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart …

Introduction Sacubitril/valsartan has been established as an effective treatment for heart
failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

Objective: Many trials confirmed the role of sacubitril–valsartan in the treatment of patients
with heart failure with reduced ejection fraction (HFrEF). However, there is no sufficient data …